Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

Revenue was down 5.9% from last year to $16.654, after increasing 10% the previous quarter. These results were better than ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

Pfizer and Novo Nordisk are in a heated legal and bidding war over Metsera, an obesity drug developer. Novo's $10 billion bid ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...